蒽环类药物相关心脏毒性早期生物标志物研究进展  

Advances in early biomarkers of anthracyclines related to cardiotoxicity

作　　者：鲁亚杰(综述) 王丽红(审校)[1] LU Yajie;WANG Lihong(Department of Hematology,Affiliated Hospital of Chengde Medical University,Chengde 067000,China)

机构地区：[1]承德医学院附属医院血液内科,承德067000

出　　处：《实用肿瘤学杂志》2023年第6期496-501,共6页Practical Oncology Journal

基　　金：河北省医学科学研究重点课题计划项目(编号:20181154)。

摘　　要：蒽环类药物是临床被广泛应用的抗肿瘤药物之一,其剂量相关心脏毒性会影响癌症患者的生活质量及生存率,故早期识别和预防蒽环类药物相关的心脏毒性显得尤为重要。本文就蒽环类药物相关心脏毒性早期生物标志物的研究进展作一综述。Anthracyclines are one of the widely used anti-tumor drugs in clinical practice.Its dose-related cardiotoxicity can affect the quality of life and survival rate of cancer patients,so early identification of anthracycline related cardiotoxicity is particularly important.This article provides a review of the research progress on early biomarkers of anthracycline related cardiotoxicity.

关 键 词：蒽环类药物 心脏毒性 生物标志物 研究进展 

分 类 号：R730.53[医药卫生—肿瘤]